What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
Her primary areas of study are Internal medicine, Oncology, Cancer, Adenocarcinoma and Pancreatic cancer.
Her research in Internal medicine intersects with topics in Gastroenterology and Germline mutation.
Her study in Oncology is interdisciplinary in nature, drawing from both Gemcitabine, Clinical endpoint, Cetuximab and DNA mismatch repair.
Her Cancer research is multidisciplinary, incorporating perspectives in Proteome, Cancer research, Proteomics and Pathology.
Her work deals with themes such as Carcinoma and Deep sequencing, which intersect with Adenocarcinoma.
Her Pancreatic cancer study combines topics in areas such as Pancreatectomy, Clinical trial and Radiation therapy.
Her most cited work include:
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) (633 citations)
- Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. (509 citations)
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205 (475 citations)
What are the main themes of her work throughout her whole career to date?
Internal medicine, Oncology, Pancreatic cancer, Cancer and Gemcitabine are her primary areas of study.
The Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
Her Oncology study which covers Germline that intersects with Olaparib and PALB2.
Her Pancreatic cancer research is multidisciplinary, incorporating elements of Cancer research, Bioinformatics, Survival rate, Adjuvant and Radiation therapy.
She combines subjects such as Pancreas, Cohort, Pathology, General surgery and Hazard ratio with her study of Cancer.
Her studies in Gemcitabine integrate themes in fields like Clinical endpoint, Cisplatin, FOLFIRINOX and Performance status.
She most often published in these fields:
- Internal medicine (85.79%)
- Oncology (66.84%)
- Pancreatic cancer (35.26%)
What were the highlights of her more recent work (between 2019-2021)?
- Internal medicine (85.79%)
- Oncology (66.84%)
- Cancer (29.30%)
In recent papers she was focusing on the following fields of study:
Eileen M. O'Reilly mostly deals with Internal medicine, Oncology, Cancer, Pancreatic cancer and Germline.
Her work is connected to Hazard ratio, Gemcitabine, Colorectal cancer, Clinical endpoint and Randomized controlled trial, as a part of Internal medicine.
Her Gemcitabine study integrates concerns from other disciplines, such as Gastroenterology and Adjuvant.
Her Oncology research integrates issues from Young adult, Metastatic pancreatic cancer, Germline mutation and Clinical trial.
Eileen M. O'Reilly has researched Cancer in several fields, including Radiation therapy and Pancreas.
Her Germline study integrates concerns from other disciplines, such as Olaparib and PALB2.
Between 2019 and 2021, her most popular works were:
- Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers (83 citations)
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation (52 citations)
- A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma (35 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Her scientific interests lie mostly in Internal medicine, Oncology, Cancer, Pancreatic cancer and Germline.
Her Internal medicine study combines topics in areas such as Gastroenterology and Gene.
Eileen M. O'Reilly interconnects Germline mutation, Borderline resectable, Pancreas and Clinical trial in the investigation of issues within Oncology.
Her work deals with themes such as Proteome and Proteomics, which intersect with Cancer.
Her Pancreatic cancer research includes themes of Chromatin, Gene expression profiling, Bone marrow and Somatic evolution in cancer.
Her research investigates the connection with Germline and areas like PALB2 which intersect with concerns in BAP1.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
